Introduction
clinically effective, safe, tolerable, convenient and costAs in other immunodeficiency states, the risk of certain effective strategies are developed. malignancies is higher than average in human immunoThis review summarizes research efforts directed at deficiency virus (HIV) infection. 1 Up to 25% of all cancers developing gene therapies for ARM. In the interest of in men under the age of 45 in the USA are associated space, strategies applicable to ARM, but not developed with HIV infection, and up to 30% of all HIV-infected specifically for them, will generally be omitted. An excelpersons will ultimately develop cancer. 3 Three maliglent overview of the oncologic aspects of HIV infection nancies, non-Hodgkin's lymphoma, Kaposi's sarcoma has been recently published. 8 and cervical carcinoma, are currently AIDS-defining, although the incidence of other cancers is likely increased as well [1] [2] [3] (see below).
AIDS-defining malignancies
A modest literature related to gene therapy for AIDSrelated malignancies (ARM) exists, and the field is Kaposi's sarcoma (KS) advancing. However, the newly formed AIDS MaligThis neoplasm develops from a cell of uncertain origin nancy Consortium is currently sponsoring no trials of and is almost always associated with evidence for infecgene therapy for any ARM, nor is the AIDS Clinicals tion with the newly-described human herpes virus-8 Trials Group. Given the modest successes of gene ther-(HHV-8 or KSHV). 9 Chemotherapy for systemic disease apies in other contexts, though, the current status of ARM has enjoyed some success, but is not curative, and is gene therapy may be reasonable. often toxic. 4 A growing concern is that the numbers of ARM cases KS tumors produce an extraordinary variety of will increase as HIV-infected individuals live longer. 4, 5 In autocrine and paracrine growth factors including cytorecognition of the expected rise in ARM, the National kines and angiogenic growth factors, and their growth Cancer Institute recently sponsored its first ever meeting may also be hormonally influenced. 4, 9, 10 Some of these devoted entirely to ARM (28-30 April 1997, Bethesda, factors, including oncostatin M, IL-6, tumor necrosis fac-MD, the abstracts of which appear in J AIDS 1997; 14).
tor-␣ and IL-1␤ enhance tumor cell, but not normal endoAlthough the meeting attracted a world-wide audience, thelial cell proliferation, 4 and thus may serve as targets fewer than five talks or abstracts were devoted to gene for specific attack. Antisense oligodeoxynucleotides therapy strategies. Given the difficulties in treating most (ODN) directed against oncostatin M inhibited both IL-6 ARM, gene therapy represents an attractive strategy to production and KS cell growth in vitro. 11 Antisense ODN against c-myc inhibited KS growth in vitro, 12 and antisense ODN against basic fibroblast growth factor inhibited growth in vitro and in vivo. The interferon releasing gene product may be a partithis approach to deliver an immunoglobulin-regulated diphtheria toxin gene to NHL-bearing SCID mice, and cularly promising target, as it appears to be involved in tumorigenesis in a mouse model. 17 Targeting of these successfully treated the tumors. 26 We recently reported on a newer generation of adenovirus vectors. 29 NHL cells genes for gene therapies must take account of the fact that some gene products will be expressed only in the induced to express HSVtk expression by these vectors were sensitized for cytotoxicity by ganciclovir. Sensitizlytic, whereas others will be expressed only in the latent cycle of HHV-8 viral replication. 4, 18 There are no pubation of EBV-transformed NHL to cytotoxicity mediated by 5-fluorocytosine using the cytosine deaminase gene lished gene therapy works targeting any of these gene products to date.
product was performed in a similar fashion. In this study, a retroviral vector was used, and a bystander killing HIV TAT is implicated in KS pathogenesis. 4 Inhibition of HIV replication via anti-tat 19 or TAR 20 gene therapies effect was seen both in vitro and in SCID mice bearing NHL tumors. 30 has been demonstrated, suggesting that such approaches may work against KS as well.
EBV genes also present an appropriate target for NHL gene therapy strategies. We used antisense ODN directed Anti-angiogenesis gene therapies which prove efficacious in other contexts, 21 may be effective in KS treatagainst the EBV gene ebna-1 to inhibit NHL growth in vitro, concurrent with reduced EBNA-1 protein ment as well, since this tumor is highly dependent on angiogenic growth factors. 4, 9 In this regard, an anti-VEGF expression. 31 Inhibiting ebna-1 with ODN also decreased tumor EBV episomal content and EBNA-2 expression, but ODN inhibited KS cell growth in vitro and in nude mice. tinct types of AIDS-related NHL: systemic, primary central nervous system (CNS) and primary effusion lymAnti-B cell antibody-toxin conjugates have also been tested. Although this work is not strictly gene therapy, phomas (PEL). Approximately half the systemic NHL are EBV-transformed, as are virtually all the primary CNS and has been studied primarily in NHL outside the context of HIV infection, it bears mentioning as these conjulymphomas and PEL. 18 In addition, PEL tumors are essentially all infected with HHV-8. 18 The EBV genes gates are effective in animal models of both low-and high-grade NHL, and are generally safe and well-tolerexpressed in NHL offer specific sites for attack by gene therapies. HHV-8 lytic or latent genes may also be suitated in phase I human clinical trials. 37 Synergy with anti-NHL chemotherapy has also been observed in animals. 38 able targets in infected cells, although little is known regarding the role of HHV-8 in lymphomagenesis. 16 In A variety of other gene therapy strategies for NHL outside the context of ARM have also been reported, includaddition, most NHL (except PEL) express a variety of B cell-specific antigens, 18 and encode B cell-specific 26 or ing inhibition of bcl-2 or IL-6 production, and p53 overexpression, 39, 40 for example, and construction of EBV-specific 27 gene regulatory elements. Examples of gene therapies capitalizing on these targets are intracellular antibodies targeting anti-apoptotic gene products. 41 described below. Whereas heterologous gene expression in KS cells has Finally, adoptive transfer of EBV-specific cytotoxic T lymphocytes (CTL) was tested in the setting of EBVproven relatively easy, 23 it has been notoriously difficult positive AIDS-related NHL. 42 Although clinical efficacy seminoma, myeloma or melanoma may be increased three-to 70-fold in HIV infection, 1, 2 and that the risk for was not clearly demonstrated in this single-patient study, adoptive transfer of EBV-specific CTL has been leiomyosarcoma in children, and squamous cell carcinoma of the conjunctiva may also be increased. 1, 3 Thus, efficacious in treatment of EBV-related NHL in other subsets of immunocompromised patients. 43 These any gene therapy strategy that decreases HIV viral burden may hinder the development or progression of canapproaches bear mentioning as the CTL may be genetically engineered. 44 cers, and may be viewed as indirect anti-ARM strategies. The subject of HIV-specific gene therapy has been extensively reviewed elsewhere.
56,57
Cervical carcinoma To our knowledge, there are no published reports regardTheoretically, any available gene therapy vector may be used in the treatment of ARM. Live, attenuated retroing gene therapy for cervical carcinoma in the setting of HIV disease. Most cervical cancers are related to infection viruses and adenoviruses are among the most efficient vectors for human gene therapy. 58 However, owing to the with the human papilloma virus (HPV), 45, 46 affording a site of specific attack. Research in the area has been hamimmunocompromised state of many HIV-infected individuals, the use of live vectors may pose substantial pered by the inability to grow HPV in culture. Clever methods using HPV promotors to drive expression of safety risks. 59 None the less, as certain live attenuated viral vaccines are safely used in some HIV-infected indireporter genes are being employed to circumvent this problem. Simultaneous expression of antisense ODN viduals, 60 the use of live, attenuated viral vectors for ARM gene therapy should not be discounted, although directed against the HPV oncogene products E6 and E7, and a sense ODN encoding the retinoblastoma gene proprudence must be exercised in the design of human clinical trials employing them. duct, inhibited growth of E6/E7-positive cervival carcinoma tumor cells in vitro and in nude mice. 46 Antisense Strategies to enhance ARM tumor immunogenicity in immunodeficient hosts have received little enthusiasm ODN against E7 also inhibited growth of HPV 18-transformed tumor cells in vitro. 47 Ribozymes cleave HPV E7 owing to their low likelihood of success. On the other hand, the possibility of a counterproductive immune mRNA from type 18 HPV, 48 which is strongly associated with cervical carcinoma. 45 response against a gene therapy vector or product may be reduced. Gene therapies to augment active host anti-A reasonable animal model has been developed by injecting human cells (either infected with HPV-bearing tumor immunity to treat ARM have not been reported to our knowledge; passive strategies were discussed primary tissue, or transformed with heterologous HPV genes) into nude mice. Antisense ODN directed against above. 42 The metabolism or pharmacokinetics of some drugs HPV E6 or E7 oncoproteins successfully treated HPVtransformed cervical cancer cells in this nude mouse may be altered in HIV infection. 6 Furthermore, HIVinfected individuals may have a propensity for adverse model. 45, 49 Other interesting approaches include adenoassociated viral vectors encoding a synthetic interferon drug reactions. 7 The potential adverse effects for gene therapy strategies in HIV disease or ARM have not been gene. Treated nude mice developed smaller tumors than control, with slower tumor growth. 50 An antisense-encowell defined. ding plasmid that interfered with production of folate receptors retarded cervical cancer tumors both in vitro Summary and perspective and in vivo. 51 Since cervical cancer is so poorly responsive to convenCertain cancers occur with increased frequency in HIVinfected individuals. These are usually incurable, and tional chemotherapy, alternative treatment strategies such as these gene therapies are needed. Cervical tumors often difficult to treat. Many of these tumors are virusrelated, or require paracrine or autocrine growth factors are anatomically easily accessible, and epithelial cells are easily transducible by several vector systems. Thus, strafor optimal growth, affording a variety of relatively tumor-specific targets. tegies using adenoviral vectors, which transduce genitourinary tract epithelial cells with extremely high Curative anticancer chemotherapeutic regimens are rarely single agent, most often being a combination of efficiency in vitro 52 and in vivo, 53 may be assessed in this disease. It was recently reported that transfer of a wildseveral agents. In combination regimens, though, the risk for drug-related toxicities is increased. A consistent probtype p53 gene into cervical carcinoma cell lines using an adenoviral vector strongly induced apoptosis in the lem in ARM treatment is poor response to chemotherapy, partly owing to the inability to give full doses of cells. 52 Similar approaches would be feasible in HIVrelated cervical cancer as well.
anticancer agents. 5 Thus, gene therapies for cancer should not be seen themselves as curative, but rather as adjuncts to conventional chemotherapies. In their adjunctive role, Other considerations they may be used to reduce the cytotoxicity of chemotherapeutic agents to produce similar efficacy with Although HIV is a lytic, rather than a transforming virus, it may contribute to oncogenesis by a variety of mechreduced toxicity as in the cases of doxorubicin and dexrazoxane 61 or cis-platinum and amifostine. 62 They may also anisms. HIV-infected stromal cells may support or augment the growth of NHL. 18 HIV TAT may play a role in be used to treat ARM with greater drug doses but without additional toxicity as with doxorubicin and dexrazox-KS. 4, 9 Activated T cells secrete cytokines that may contribute to the development of either KS or NHL.
54,55 HIVane, 61 to enhance tumor sensitivity to gamma irradiation as with 5-fluorouracil, 63 to enhance the cytotoxicity of cerinduced immunodeficiency increases cancer risk as discussed above. 1, 2 In fact, epidemiologic data now suggest tain chemotherapeutic agents as in the case of leucovorin and 5-fluorouracil, 64 or to enhance immunologic tumor that the risk for developing Hodgkin's disease, anal squamous cell carcinoma, oropharyngeal carcinoma, clearance mechanisms as with IL-2 65,66 or interferon-␥.
